Full-Time

Business Development Manager

Deadline 4/14/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Remote in USA + 2 more

More locations: California, USA | Newport Beach, CA, USA

Remote

Remote in the United States; preference for West Coast.

Category
Business & Strategy (1)
Required Skills
Salesforce
Business Analytics
Requirements
  • Bachelor’s degree in a life sciences related field.
  • An MBA or a Master’s/PhD in a scientific discipline is highly advantageous.
  • Minimum 5 years of experience in sales or business development serving academic, government, or pharmaceutical scientific markets.
  • Demonstrated ability to assess research needs and translate them into effective commercial strategies.
  • Proficiency with Salesforce CRM and business analytics tools for managing pipelines, forecasting, and account planning, as well as Microsoft Office suite.
  • Willingness to travel up to 50% for campus visits, seminars, conferences, customer meetings, and team activities.
Responsibilities
  • Identify and pursue new business opportunities across academic departments, shared resource facilities, government labs, and pharma research organizations.
  • Generate and qualify leads through scientific networking, campus visits, conferences, workshops, and digital outreach.
  • Develop and execute strategies to broaden adoption of bioanalytical technologies in research-intensive organisations.
  • Maintain an accurate sales pipeline and provide reliable forecasting for the target customer segment.
  • Collaborate with regional sales and marketing teams to convert academic and research opportunities into orders.
  • Support the sales process through technical presentations, workflow discussions, demonstrations, and proposal/quote negotiation.
  • Develop and implement sales plans tailored to academic funding cycles, grant landscapes, and institutional priorities.
  • Set and monitor target performance to ensure goals aligned with the Annual Operating Plan are achieved or exceeded.
  • Deliver remote and in person‑ training for sales and marketing teams focused on academic bioanalytical workflows, research applications, and adoption drivers.
  • Provide tools, content, and positioning strategies designed specifically for academic and government research environments.
  • Use virtual platforms, academic seminar programs, webinars, and outreach events to expand awareness and build the funnel in academic and pharmaceutical discovery markets
  • Create and execute promotional initiatives aligned with academic research trends and institutional needs.
  • Build and maintain strong, long term‑ relationships with principal investigators, lab managers, core directors, and research administration.
  • Collect and communicate customer insights, research challenges, and success stories to guide commercial strategy.
  • Ensure exceptional customer service to support recurring business and long‑term partnerships.
  • Provide regular updates on performance, market dynamics, grant trends, and customer feedback to the Pharma Program Lead.
  • Use data-driven insights to adjust strategies and maximize success in the target customer segment.
  • Maintain a strong working knowledge of quantitative and qualitative LC‑MS, flow cytometry, and complementary analytical technologies.
  • Communicate technical and workflow advantages effectively to scientific audiences with varying levels of expertise.
  • Capture feedback from researchers, core facility staff, and field sales teams to support ongoing refinement of bioanalytical solutions.
  • Partner with sales, marketing, product management, and the broader Waters Analytical Science business segment to deliver cohesive, research-focused solutions to customers.
Desired Qualifications
  • An MBA or a Master’s/PhD in a scientific discipline is highly advantageous.

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
  • Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
  • China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.

What critics are saying

  • Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
  • $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
  • BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.

What makes Waters Corporation unique

  • BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
  • omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
  • ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Waters Corporation who can refer or advise you

Benefits

Hybrid Work Options

Company News

PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.